870 related articles for article (PubMed ID: 27318707)
1. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
Pålhagen SE; Sydow O; Johansson A; Nyholm D; Holmberg B; Widner H; Dizdar N; Linder J; Hauge T; Jansson R; Bergmann L; Kjellander S; Marshall TS
Parkinsonism Relat Disord; 2016 Aug; 29():17-23. PubMed ID: 27318707
[TBL] [Abstract][Full Text] [Related]
2. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes.
Antonini A; Yegin A; Preda C; Bergmann L; Poewe W;
Parkinsonism Relat Disord; 2015 Mar; 21(3):231-5. PubMed ID: 25585993
[TBL] [Abstract][Full Text] [Related]
3. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N
Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758
[TBL] [Abstract][Full Text] [Related]
4. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.
Fernandez HH; Standaert DG; Hauser RA; Lang AE; Fung VS; Klostermann F; Lew MF; Odin P; Steiger M; Yakupov EZ; Chouinard S; Suchowersky O; Dubow J; Hall CM; Chatamra K; Robieson WZ; Benesh JA; Espay AJ
Mov Disord; 2015 Apr; 30(4):500-9. PubMed ID: 25545465
[TBL] [Abstract][Full Text] [Related]
5. The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review.
Antonini A; Odin P; Pahwa R; Aldred J; Alobaidi A; Jalundhwala YJ; Kukreja P; Bergmann L; Inguva S; Bao Y; Chaudhuri KR
Adv Ther; 2021 Jun; 38(6):2854-2890. PubMed ID: 34018146
[TBL] [Abstract][Full Text] [Related]
6. Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study.
Lopiano L; Modugno N; Marano P; Sensi M; Meco G; Solla P; Gusmaroli G; Tamma F; Mancini F; Quatrale R; Zangaglia R; Bentivoglio A; Eleopra R; Gualberti G; Melzi G; Antonini A
J Neurol; 2019 Sep; 266(9):2164-2176. PubMed ID: 31134377
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients.
Slevin JT; Fernandez HH; Zadikoff C; Hall C; Eaton S; Dubow J; Chatamra K; Benesh J
J Parkinsons Dis; 2015; 5(1):165-74. PubMed ID: 25588353
[TBL] [Abstract][Full Text] [Related]
8. An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients.
Krüger R; Lingor P; Doskas T; Henselmans JML; Danielsen EH; de Fabregues O; Stefani A; Sensken SC; Parra JC; Onuk K; Yegin A; Antonini A
Adv Ther; 2017 Jul; 34(7):1741-1752. PubMed ID: 28631218
[TBL] [Abstract][Full Text] [Related]
9. Long-term effectiveness of levodopa-carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's disease.
Valldeoriola F; Grandas F; Santos-García D; Regidor I; Catalán MJ; Arbelo JM; Puente V; Mir P; Parra JC
Neurodegener Dis Manag; 2016 Aug; 6(4):289-98. PubMed ID: 27440190
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
[TBL] [Abstract][Full Text] [Related]
11. Advanced therapies in Parkinson's disease: Long-term retrospective study.
Merola A; Espay AJ; Romagnolo A; Bernardini A; Rizzi L; Rosso M; Espay KJ; Zibetti M; Lanotte M; Lopiano L
Parkinsonism Relat Disord; 2016 Aug; 29():104-8. PubMed ID: 27215392
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson’s disease patients.
Sücüllü Karadağ Y; Saltoğlu T; Erdoğan Küçükdağli F; Öztürk Ö; Köseoğlu HT; Altiparmak E
Turk J Med Sci; 2021 Feb; 51(1):84-89. PubMed ID: 32718129
[TBL] [Abstract][Full Text] [Related]
13. Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry.
Antonini A; Poewe W; Chaudhuri KR; Jech R; Pickut B; Pirtošek Z; Szasz J; Valldeoriola F; Winkler C; Bergmann L; Yegin A; Onuk K; Barch D; Odin P;
Parkinsonism Relat Disord; 2017 Dec; 45():13-20. PubMed ID: 29037498
[TBL] [Abstract][Full Text] [Related]
14. [The impact of levodopa-carbidopa intestinal gel on health-related quality of life in Parkinson's disease].
Kovács N; Aschermann Z; Ács P; Bosnyák E; Deli G; Janszky J; Komoly S
Ideggyogy Sz; 2014 Jul; 67(7-8):245-50. PubMed ID: 25509365
[TBL] [Abstract][Full Text] [Related]
15. Initiation of Levodopa-Carbidopa Intestinal Gel Infusion Using Telemedicine (Video Communication System) Facilitates Efficient and Well-Accepted Home Titration in Patients with Advanced Parkinson's Disease.
Willows T; Dizdar N; Nyholm D; Widner H; Grenholm P; Schmiauke U; Urbom A; Groth K; Larsson J; Permert J; Kjellander S
J Parkinsons Dis; 2017; 7(4):719-728. PubMed ID: 28984615
[TBL] [Abstract][Full Text] [Related]
16. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.
Băjenaru O; Ene A; Popescu BO; Szász JA; Sabău M; Mureşan DF; Perju-Dumbrava L; Popescu CD; Constantinescu A; Buraga I; Simu M
J Neural Transm (Vienna); 2016 Apr; 123(4):407-14. PubMed ID: 26699635
[TBL] [Abstract][Full Text] [Related]
17. Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel.
Ray Chaudhuri K; Antonini A; Robieson WZ; Sanchez-Soliño O; Bergmann L; Poewe W;
Eur J Neurol; 2019 Apr; 26(4):581-e43. PubMed ID: 30353942
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
Fernandez HH; Boyd JT; Fung VSC; Lew MF; Rodriguez RL; Slevin JT; Standaert DG; Zadikoff C; Vanagunas AD; Chatamra K; Eaton S; Facheris MF; Hall C; Robieson WZ; Benesh J; Espay AJ
Mov Disord; 2018 Jul; 33(6):928-936. PubMed ID: 29570853
[TBL] [Abstract][Full Text] [Related]
19. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV
Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691
[TBL] [Abstract][Full Text] [Related]
20. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience.
Zibetti M; Merola A; Artusi CA; Rizzi L; Angrisano S; Reggio D; De Angelis C; Rizzone M; Lopiano L
Eur J Neurol; 2014 Feb; 21(2):312-8. PubMed ID: 24313838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
